Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08816_nanopub.RA79Gehj8QSIRGnRKky5YW4kM8L7rq1VOmLlPLGW6AqXY#assertion>. }
Showing items 1 to 19 of
19
with 100 items per page.
- drugbank:DB08816 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08816 label "Ticagrelor [drugbank:DB08816]" assertion.
- drugbank:DB08816 seeAlso DB08816 assertion.
- drugbank:DB08816 seeAlso ticagrelor.html assertion.
- drugbank:DB08816 seeAlso brilinta-drug.htm assertion.
- drugbank:DB08816 identifier "drugbank:DB08816" assertion.
- drugbank:DB08816 description "Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011." assertion.
- drugbank:DB08816 title "Ticagrelor" assertion.
- drugbank:DB08816 bio2rdf_vocabulary:identifier "DB08816" assertion.
- drugbank:DB08816 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08816 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08816" assertion.
- drugbank:DB08816 bio2rdf_vocabulary:x-identifiers.org DB08816 assertion.
- drugbank:DB08816 drugbank_vocabulary:drugbank-id "DB08816" assertion.
- drugbank:DB08816 drugbank_vocabulary:x-cas cas:274693-27-5 assertion.
- drugbank:DB08816 drugbank_vocabulary:x-ahfs ahfs:20:12:18 assertion.
- drugbank:DB08816 drugbank_vocabulary:x-atc atc:B01AC24 assertion.
- drugbank:DB08816 drugbank_vocabulary:x-kegg kegg:D09017 assertion.
- drugbank:DB08816 drugbank_vocabulary:x-wikipedia wikipedia:Ticagrelor assertion.
- drugbank:DB08816 drugbank_vocabulary:x-ndc ndc:0186-0777-08 assertion.